Defined, sampling is the process of taking a small but representative portion of a much larger stream, where the sample collected accurately represents the content of the larger stream. Effective sampling is a very important part of process validation in pharmaceutical manufacturing. Sampling is a mandated element of FDA Good Manufacturing Practices, but the FDA does not legislate a specific approach to establishing a sampling plan. Whatever approach is selected must be clearly and easily justified. We use two main sampling techniques in the industry today: a risk-based method and a statistical approach. What’s the difference between the two? In risk-based sampling, the design of the sampling plan is based upon sound principles and the experience of the Subject Matter Experts. Facilities using this method will have a baseline number for sample size based upon risk and performance, and that number can change based on prior inspection results – it may be reduced due to good results, or tightened due to poor results. Implementing a risk-based method can help companies spend less time and money, but it often makes sampling systems difficult to track. We also have the option of using statistically-based sampling to validate our processes. Rather than basing samples on risks and performance, this method gathers data from each individual lot from a probability standpoint to ensure that the sample is unbiased representation of the entire batch. This method may provide a more concrete representation, however, using this approach can prove difficult for companies that manufacture a variety of products. Risk-based and statistical sampling both have their benefits and drawbacks. So when should one method be used over another? Find out in just a few weeks at the ISPE/PQRI Process Validation Conference, where Global Lead Statistician James Crichton will speak on the most appropriate and effective uses for each method. Join us from October 7 – 8 in Silver Spring, Maryland. Register Now!
In the pharmaceutical industry, which is highly regulated, aseptic processing is a critical component that ensures the sterility of products. Regulators have a set of comprehensive requirements that minimize the risk of contamination. Regulators set the requirements; however, the industry has an obligation to the patients who rely on and expect a drug that is safe and free of contamination....
Like any investment in digital manufacturing systems, demonstrating business payback before and after investment is critical to getting MES projects approved and verifying profitability after investment. Whether it is introducing MES, expanding it to additional sites, switching software, upgrading existing software, or developing electronic production records (EPR) for new drug products,...
Sustainability is emerging as a pivotal force influencing the pharmaceutical industry’s dynamics and steering companies towards transformative change. The focus of this analysis is to delve into the sustainability key performance indicators (KPIs) of prominent pharmaceutical players, namely Pfizer, Sanofi, Glaxo Smith Kline (GSK), Becton Dickinson, Johnson & Johnson, Abbott, Eli Lilly, and...